Amit Shard, PhD

About

A detail-oriented medicinal chemist specializing in the design, synthesis, computational validation, and characterization of novel, drug-like compounds for applications in cancer, pain management, and spinal cord injury. Proficient in drug design, with a primary focus on developing therapeutic molecules targeting pyruvate kinase M2 (PKM2). Skilled at innovating new applications and products, generating intellectual property, and delivering technical solutions in drug discovery and synthesis.

Employment

• National Institute of Pharmaceutical Education and Research Ahmedabad Associate Professor
  2014 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (83)

• Rhynchophylline inhibits cluster of differentiation 36 (CD36) on endothelial cells to reduce fibrotic scar formation and enhance functional recovery after spinal cord injury
  Phytomedicine 2026 DOI: 10.1016/j.phymed.2026.158219
  +Save
• Coumarin–sulfonamide hybrids as PKM2 activators induce metabolic reprogramming and suppress ovarian cancer cell growth
  Bioorganic & Medicinal Chemistry 2026 DOI: 10.1016/j.bmc.2026.118733
  +Save
• 2,5-Diazabicyclo[2.2.1]heptane in medicinal chemistry: a treasure trove of therapeutic opportunities
  RSC Medicinal Chemistry 2026 DOI: 10.1039/D5MD00992H
  +Save
• Pyruvate kinase M2 – linked metabolic pathways in pain modulation
  Drug Discovery Today 2026 DOI: 10.1016/j.drudis.2025.104557
  +Save
• Sustainable synthesis and biological evaluation of novel ferrocene derivatives as metabolic modulators of pyruvate kinase M2 in oral cancer
  Inorganic Chemistry Communications 2026 DOI: 10.1016/j.inoche.2026.116605
  +Save
• Exploring Ugi-driven tetrazole chemistry for the discovery of pyruvate kinase M2 activators in glioblastoma management
  Journal of Molecular Structure 2026 DOI: 10.1016/j.molstruc.2025.144795
  +Save
• Thiazole-Based Tumor Pyruvate Kinase M2 Inhibitors: A Paradigm-Shifting Therapeutic Strategy Targeting Metabolic and Microbial Synergy in Colorectal Cancer
  Journal of Medicinal Chemistry 2025 DOI: 10.1021/acs.jmedchem.5c02169
  +Save
• Development of novel tetrazole-based pyruvate kinase M2 inhibitors targeting U87MG glioblastoma cells
  Bioorganic Chemistry 2025 DOI: 10.1016/j.bioorg.2024.108029
  +Save
• Carbohydrate kinase inhibition: a promising strategy in cancer treatment
  Drug Discovery Today 2025 DOI: 10.1016/j.drudis.2025.104308
  +Save
• Physicochemical Characterization, Metabolite Profiling, and Preclinical Pharmacokinetic Assessment of a Sulfonamide‐Based Pyruvate Kinase M2 Activator for Anticancer Lead Identification
  ChemistrySelect 2025 DOI: 10.1002/slct.202406039
  +Save